{"id":1015189,"date":"2026-10-29T12:16:27","date_gmt":"2026-10-29T16:16:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/"},"modified":"2026-10-29T12:16:27","modified_gmt":"2026-10-29T16:16:27","slug":"scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/","title":{"rendered":"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>JERSEY CITY, N.J., Oct.  29, 2026  (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.<\/p>\n<p>\n        <strong>One-on-One Meetings<\/strong><br \/>\n        <br \/>Dates: November 9-10, 2026<\/p>\n<p>\n        <strong>Fireside Chat<\/strong><br \/>\n        <br \/>Date: Monday, November 9, 2026<br \/>Time: 2:30 p.m.-3:00 p.m. ET<\/p>\n<p>A live webcast of the Guggenheim fireside chat will be available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RXrjXKG9rRKiFbGBNd5NS8vi7HWdfGWYetyqpDdhyvViN080QAqwxi2M0GaywSB5F1w1CSFg1vVONKp7GeSVhvbmY_rSPXXuufFflolCsW59Din0rHo4ulW6PzTYDLRtZbhFm7lfysDk4ACgtd8paw==\" rel=\"nofollow\" target=\"_blank\">here<\/a>. A replay of the webcast will be available on our website for 90 days following the event.<\/p>\n<p>\n        <strong>About SCYNEXIS<\/strong>\n      <\/p>\n<p>SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS\u2019s proprietary antifungal platform \u201cfungerps\u201d includes BREXAFEMME\u00ae (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wfFPVMLxzhdp_3zeL-Rmt0yo3CAhKXKPqFInU5EPFP2czu58THN7xDH_kcfBOPgHOVodOomwuX_3N8bwBeDM2bazUkQfXMAo8uZI1gWG82U=\" rel=\"nofollow\" target=\"_blank\">www.scynexis.com<\/a>.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>John Fraunces<br \/>LifeSci Advisors<br \/>Tel: 917-355-2395<br \/>jfraunces@lifesciadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGZkNjk5MmMtZjNlYy00NDQ2LWE0YjYtMGM1NTI3MWVlOWM2LTUwMDA3MDcxOC0yMDI2LTEwLTI5LWVu\/tiny\/Scynexis-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston. One-on-One Meetings Dates: November 9-10, 2026 Fireside Chat Date: Monday, November 9, 2026Time: 2:30 p.m.-3:00 p.m. ET A live webcast of the Guggenheim fireside chat will be available here. A replay of the webcast will be available on our website for 90 days following the event. About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015189","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston. One-on-One Meetings Dates: November 9-10, 2026 Fireside Chat Date: Monday, November 9, 2026Time: 2:30 p.m.-3:00 p.m. ET A live webcast of the Guggenheim fireside chat will be available here. A replay of the webcast will be available on our website for 90 days following the event. About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being &hellip; Continue reading &quot;SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-29T16:16:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference\",\"datePublished\":\"2026-10-29T16:16:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/\"},\"wordCount\":205,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/\",\"name\":\"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==\",\"datePublished\":\"2026-10-29T16:16:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/","og_locale":"en_US","og_type":"article","og_title":"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference - Market Newsdesk","og_description":"JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) &#8212; SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston. One-on-One Meetings Dates: November 9-10, 2026 Fireside Chat Date: Monday, November 9, 2026Time: 2:30 p.m.-3:00 p.m. ET A live webcast of the Guggenheim fireside chat will be available here. A replay of the webcast will be available on our website for 90 days following the event. About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being &hellip; Continue reading \"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-29T16:16:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference","datePublished":"2026-10-29T16:16:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/"},"wordCount":205,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/","name":"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==","datePublished":"2026-10-29T16:16:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NTk0NSM3OTIzMTM0IzUwMDA3MDcxOA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scynexis-to-participate-in-the-3rd-annual-guggenheim-healthcare-innovation-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015189"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015189\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}